Nuformix (LON:NFX) Now Covered by Analysts at Canaccord Genuity Group

Research analysts at Canaccord Genuity Group started coverage on shares of Nuformix (LON:NFX) in a research note issued to investors on Tuesday,Digital Look reports. The firm set a “buy” rating and a GBX 293 ($3.81) price target on the stock.

Nuformix Trading Down 7.2 %

Shares of LON:NFX traded down GBX 0.01 ($0.00) during trading on Tuesday, hitting GBX 0.08 ($0.00). 21,672,947 shares of the stock were exchanged, compared to its average volume of 53,205,668. The company has a fifty day moving average price of GBX 0.08 and a two-hundred day moving average price of GBX 0.07. The company has a market cap of £948,493.00, a PE ratio of -2.34 and a beta of 1.22. Nuformix has a 12-month low of GBX 0.04 ($0.00) and a 12-month high of GBX 0.30 ($0.00).

Nuformix (LON:NFX) last announced its quarterly earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) EPS for the quarter.

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.